It is generally accepted that increased RAS activity and suppression of NO levels are common features of cardiovascular diseases including essential hypertension.1,21 We therefore examined the effect of cotreatment with L‐NAME, a NO synthase inhibitor, and Ang II on cardiovascular remodeling in control and MyPHD2KO mice. The gene discussed is AGT; the disease is essential hypertension.